Evidence map›Paper›PMID 30713830›Full record

ArticleTranslational cancer research2016

Novel insights into the oncogenic function of the SMYD3 lysine methyltransferase.

Pawel K Mazur, Or Gozani, Julien Sage, Nicolas Reynoird

Abstract readComment
In one paragraph

Article in Translational cancer research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Pawel K MazurDepartments of Pediatrics, Stanford University School of Medicine, CA 94305, USA.
Or GozaniDepartment of Biology, Stanford University, CA 94305, USA.
Julien SageDepartments of Pediatrics, Stanford University School of Medicine, CA 94305, USA.
Nicolas ReynoirdInstitute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Université Grenoble Alpes, 38700 Grenoble Cedex, France.

Funding

Mechanisms of action of the Smyd3 methyltransferase in cancer cellsR01CA172560 · NCI · STANFORD UNIVERSITY · PI GOZANI, OR P., SAGE, JULIEN · 2013 to 2017
$2.3M
The SMYD3-ERK5 signaling module in pancreatic cancerK99CA197816 · NCI · STANFORD UNIVERSITY · PI MAZUR, PAWEL K. · 2015 to 2016
$294k
NCI NIH HHS K99 CA197816NCI NIH HHS R01 CA172560
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID30713830
PMCPMC6358167

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.